Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Bode

Showing results (551-560 of 589) with videos related to

Pageof 59
Sort By:
Diabetes Care|October 18, 2024
Efficacy and Safety of a Tubeless AID System Compared With Pump Therapy With CGM in the Treatment of Type 1 Diabetes in Adults With Suboptimal Glycemia: A Randomized, Parallel-Group Clinical TrialEric Renard, Ruth S Weinstock, Grazia Aleppo, et al.
Diabetes Technology & Therapeutics|August 1, 2018
Accuracy of a Fourth-Generation Continuous Glucose Monitoring System in Children and Adolescents with Type 1 DiabetesRobert H Slover, Jeanie B Tryggestad, Linda A DiMeglio, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 25, 2024
Metagenomic study of lake microbial mats reveals protease-inhibiting antiviral peptides from a core microbiome memberChandrashekhar Padhi, Christopher M Field, Clarissa C Forneris, et al.
Nature Medicine|October 3, 2022
Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trialJeremy Pettus, Schafer C Boeder, Mark P Christiansen, et al.
Diabetes Technology & Therapeutics|October 10, 2018
In-Clinic Evaluation of the MiniMed 670G System "Suspend Before Low" Feature in Children with Type 1 DiabetesMichael A Wood, Dorothy I Shulman, Gregory P Forlenza, et al.
Nature Medicine|March 18, 2023
Publisher Correction: Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trialJeremy Pettus, Schafer C Boeder, Mark P Christiansen, et al.
JCI Insight|December 20, 2019
Immunomodulatory activity of humanized anti-IL-7R monoclonal antibody RN168 in subjects with type 1 diabetesKevan C Herold, Samantha L Bucktrout, Xiao Wang, et al.
Diabetes Care|July 12, 2014
Real-time continuous glucose monitoring among participants in the T1D Exchange clinic registryJenise C Wong, Nicole C Foster, David M Maahs, et al.
Diabetes Care|March 26, 2015
Response to comment on Wong et al. Real-time continuous glucose monitoring among participants in the T1D exchange clinic registry. Diabetes Care 2014;37:2702-2709Jenise C Wong, Nicole C Foster, David M Maahs, et al.
Nature|January 29, 2025
C-terminal amides mark proteins for degradation via SCF-FBXO31Matthias F Muhar, Jakob Farnung, Martina Cernakova, et al.
Pageof 59

Showing results (551-560 of 589) with videos related to

Sort By:
Pageof 59
Diabetes Care|October 18, 2024
Efficacy and Safety of a Tubeless AID System Compared With Pump Therapy With CGM in the Treatment of Type 1 Diabetes in Adults With Suboptimal Glycemia: A Randomized, Parallel-Group Clinical TrialEric Renard, Ruth S Weinstock, Grazia Aleppo, et al.
Diabetes Technology & Therapeutics|August 1, 2018
Accuracy of a Fourth-Generation Continuous Glucose Monitoring System in Children and Adolescents with Type 1 DiabetesRobert H Slover, Jeanie B Tryggestad, Linda A DiMeglio, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 25, 2024
Metagenomic study of lake microbial mats reveals protease-inhibiting antiviral peptides from a core microbiome memberChandrashekhar Padhi, Christopher M Field, Clarissa C Forneris, et al.
Nature Medicine|October 3, 2022
Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trialJeremy Pettus, Schafer C Boeder, Mark P Christiansen, et al.
Diabetes Technology & Therapeutics|October 10, 2018
In-Clinic Evaluation of the MiniMed 670G System "Suspend Before Low" Feature in Children with Type 1 DiabetesMichael A Wood, Dorothy I Shulman, Gregory P Forlenza, et al.
Nature Medicine|March 18, 2023
Publisher Correction: Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trialJeremy Pettus, Schafer C Boeder, Mark P Christiansen, et al.
JCI Insight|December 20, 2019
Immunomodulatory activity of humanized anti-IL-7R monoclonal antibody RN168 in subjects with type 1 diabetesKevan C Herold, Samantha L Bucktrout, Xiao Wang, et al.
Diabetes Care|July 12, 2014
Real-time continuous glucose monitoring among participants in the T1D Exchange clinic registryJenise C Wong, Nicole C Foster, David M Maahs, et al.
Diabetes Care|March 26, 2015
Response to comment on Wong et al. Real-time continuous glucose monitoring among participants in the T1D exchange clinic registry. Diabetes Care 2014;37:2702-2709Jenise C Wong, Nicole C Foster, David M Maahs, et al.
Nature|January 29, 2025
C-terminal amides mark proteins for degradation via SCF-FBXO31Matthias F Muhar, Jakob Farnung, Martina Cernakova, et al.
Pageof 59